ADITEC MEETING 2018
Advanced Immunization Technologies
Siena, 1-3 October 2018
Aula Magna Rettorato, University of Siena
Via Banchi di Sotto 55

Agenda
1st October 2018 – Day 1

14:00 – 15:30 Registration and Buffet Lunch

15:30 - 16:30 Opening Session

15:30 Welcome Address
Francesco Frati
Rector of the University of Siena

Luisa Bracci
Director Department of Medical Biotechnology

Pierre Meulien
IMI 2 Executive Director

Rino Rappuoli
GlaxoSmithKline

Donata Medaglini
University of Siena, SVA

15:45 IMI 2 Prospective

16:00 Vaccines 2030

16:15 Impact and perspectives of the ADITEC network

16:30 - 18:10 Vaccine Adjuvants

Chairs: Ali Harandi, University of Gothenburg; Peter Andersen, Statens Serum Institute

16:30 Introduction
Peter Andersen
Statens Serum Institute

Ali Harandi
University of Gothenburg

16:40 Multi-Omics Systems Analysis of Clinically Tested Vaccine Adjuvants

Steven Reed
IDRI Infectious Disease Institute

16:55 The Science and Progress of Vaccine Adjuvants
Emilio Siena
GlaxoSmithKline

17:10 Systems Analysis of GSK Vaccine Adjuvants

Dennis Christensen
Statens Serum Institute

17:25 A novel cationic based adjuvant formulation containing two delivery systems, with the ability to induce mucosal IgA following a parenteral immunization
Dennis Christensen

17:40 Opportunities from the Nanobiotechnology JRC-ISPRA for characterization of adjuvants
Arnd Hoeveeler
JRC-ISPRA

18:30 Welcome Cocktail- Cortile Palazzo del Rettorato, University of Siena
2nd October 2018 – Day 2

8:30 - 09:45 Vaccine Delivery

*Chairs: Alfredo Nicosia, Nouscom/Reithera; Steven Reed, IDRI*

08:30 Novel Viral Vectors for cancer vaccines

08:45 Integrate defective lentiviral vector (IDLV) as a vaccine platform for delivering viral antigens

09:00 RNAActive®- An mRNA-based vaccine technology for next generation prophylactic vaccines

09:15 Preclinical evaluation of a new therapeutic vaccine based on immunostimulant nanoparticles against chronic HBV infections

09:30 General Discussion

09:45 - 10:15 Coffee Break

10:15 - 11:45 Priming the Immune System

*Chairs: Thomas Lehner, King’s College London; Robin Shattock, Imperial College*

10:15 Positively Primed

10:30 Modulation of primary immune response by different adjuvants to design heterologous prime-boost combinations

10:45 Differential imprinting of CD4+ T cell lung-homing capacity by conventional dendritic cells from inguinal and mediastinal lymph nodes

11:00 Innate responses to vaccine differ at each immunization

11:15 Blood transcriptomic analysis shows how recall innate responses are modulated by the use of an adjuvant at priming

11:30 General Discussion

11:45 - 13:00 Challenge Models

*Chair: Roger LeGrand, CEA Atomic Energy Commission*

11:45 Human Challenge Models

12:00 Bordetella pertussis challenge fails to recall vaccine- and pre-exposure-induced circulating memory B cells

12:15 Airway T cells protect against RSV infection in the absence of antibody

12:30 Vaccination of susceptible 129S2 mice with BCG reveals that female mice are better protected after vaccination than males.

12:45 General Discussion

13:00 - 14:00 Lunch

13:00 - 14:00 Steering Committee Meeting Lunch
14:00 - 14:45  Poster Session
14:45 - 15:45  Systems Biology and Mathematical Models for the Analysis of Vaccine Responses

Chairs: Andrew Pollard, University of Oxford; Simone Furini, University of Siena

14:45  Transcriptomic analysis of the blood immune response to the rVSV-ZEBOV Ebola vaccine  Francesco Santoro
15:00  Direct RNA Sequencing for Genome-wide Expression and Transcriptional Landscape analysis  Intawat Nookaew
15:15  AGACY: A python tool for Automating Gating and Analysis of flow Cytometry data  Simone Furini
15:30  General Discussion

15:45 - 16:15  Coffee Break

16:15 - 17:30  Vaccination in Elderly and Early Life

Chair: Claire-Anne Siegrist, University of Geneva

16:15  Vaccine response in very young  Claire-Anne Siegrist
16:30  The early life lymph node barrier is permeable and may result into the systemic diffusion of antigens and adjuvants  Floriane Auderset
16:45  Impaired immune response to primary but not to booster vaccination against hepatitis B in older adults  Marielle Haks
17:00  Inhibitory influence of maternal antibodies on T and B cell vaccine responses: how is it mediated?  Maria Vono
17:15  General Discussion

17:30 - 18:30  Round-table: Fostering Vaccine Research in Europe

Chair: Rino Rappuoli, GlaxoSmithKline

Panelists:

Pierre Meuilen  Innovative Medicines Initiative 2
Arun Kumar  Coalition for Epidemic Preparedness Innovation (CEPI)
Arnd Hoeveler  JRC ISPRA
Philippe Denoel  Vaccine Europe

18:30 – 18:40  Concluding Remarks  Monica Barni

Vice-President of the Tuscan Region

19:15  Guided Tour Collection of Art Works, Palazzo Sansedoni

20:00  Social Dinner- Palazzo Sansedoni, Fondazione Monte dei Paschi di Siena
3rd October 2018 – Day 3

08:30 - 10:00 Biomarkers of Human of Immune-response to Vaccination

Chairs: Tom Ottenhoff, University of Leiden; Sheri Dubey, Merck

08:30 Comparison of Ebola Vaccine Responses in Non-Human Primate Studies and Human Clinical Trials

08:45 Exploring new markers of innate responses to the VSV-ZEBOV EBOLA vaccine

09:00 Characterization of avidity and functional epitope targeting properties of rVSV-Ebola vaccine-induced antibodies in humans

09:15 Safety and immunogenicity of chlamydia vaccine candidate CTH522 adjuvanted with Alum or CAF01: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 study

09:30 Safety and memory response of a booster vaccination with GVGH Shigella sonnei 1790GAHB in healthy adults previously primed with three doses of the same vaccine compared to naive individuals vaccinated for the first time.

09:45 General Discussion

10:00 - 10:45 Biomarkers of Vaccine safety

Chairs: Giuseppe Del Giudice, GlaxoSmithKline, Ingelief Jonsdottir, DeCODE Genetics

10:00 Main achievements of the Biovacsafe Project

10:15 Biomarkers of vaccine safety - What can gene expression analysis add to the picture?

10:30 Cross-species transcriptomic signatures in blood, muscle and draining lymphnodes after administration of licensed vaccines

10:45 - 11:15 Coffee Break

11:15 - 12:30 Synergies with other EU Vaccine Projects

Chair: Pierre Meulien, Innovative Medicine Initiative 2

11:15 Vaccine Safety and Immunogenicity Signatures of Adult and Pediatric Responses to the rVSV-ZEBOV Ebola Vaccine ((VSV-EOBVAC and VSV-EOPLUS)

11:25 TuBercolosis Vaccine Initiative (TBVAC2020)

11:35 Innovation Partnership for a Roadmap on Vaccines in Europe (IPROVE)

11:45 European Network of Vaccine Development and Research (TRANSVAC II)

11:55 Novel Vaccine Vectors to Resist Pathogen Challenge (VacPath)

12:05 Standardization and development of assays for assessment of influenza vaccine correlates of protection (FLUCOP)

12:15 General Discussion

12:30 - 12:45 Concluding Remarks

13:00 - 14:00 Lunch

14:00 – 15:00 SVA Associate Member Assembly (SVA Members only)
Under the auspices of the International Union of Immunological Societies

The ADITEC project has received funding from the European Union’s Seventh Program for Research, Technological Development and Demonstration under grant agreement No. 280873.